CASE REPORT

A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour

A H G Hansma¹, Y van Hensbergen¹, B C Kuenen¹, P J van Diest², R Hanemaaijer⁴, S Meijer³, H M Pinedo¹ and K Hoekman¹

¹ Department of Medical Oncology, Vrije Universiteit Medical Centre, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands
² Department of Pathology, Vrije Universiteit Medical Centre
³ Department of Surgery, Vrije Universiteit Medical Centre
⁴ Gaubius Laboratory, TNO-PG, Leiden, The Netherlands

Correspondence to:
Correspondence to:
Dr K Hoekman
Department of Medical Oncology, Vrije Universiteit Medical Centre, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands; k.hoekman{at}vumc.nl

Tumour associated neovascularisation has been characterised as chaotic and insufficient. This report details the results of the analysis of angiogenic factors in tumour cyst fluid, pleural fluid, and blood from a patient with a gastrointestinal autonomic nerve tumour. The tumour produced vascular endothelial growth factor and endostatin in large quantities, which may explain the dysfunctional angiogenesis and tendency to bleeding seen in this tumour type.

Keywords: gastrointestinal autonomic nerve tumour; vascular endothelial growth factor; endostatin; tumour fluid

Abbreviations: bFGF, basic fibroblast growth factor; ELISA, enzyme linked immunosorbent assay; GANT, gastrointestinal autonomic nerve tumour; MMP, matrix metalloprotease; ms-mono, mouse monoclonal antibody; NSE, neurone specific enolase; PS, plasminogen activator; STS, soft tissue sarcomas; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator; VEGF, vascular endothelial growth factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hansma, A. H. G., Broxterman, H. J., van der Horst, I., Yuana, Y., Boven, E., Giaccone, G., Pinedo, H. M., Hoekman, K. (2005). Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol 16: 1695-1701 [Abstract] [Full Text]